From Earlier: Wedbush Reiterates BioMarin Pharmaceuticals Neutral, FV To $35

Wedbush reiterated its BioMarin Pharmaceuticals

Neutral rating and reduced its fair value from $36 to $35 in a research report published today. In the report, Wedbush stated, "Among the numerous catalysts in the remainder of 2012, we believe release of Phase 3 results from the GALNS trial in Q4 is likely to have the strongest impact on BMRN valuation." Shares of BioMarin closed today at $36.34, down 0.03% from Thursday's market close.